DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Etodolac (Etodolac) - Summary

 
 



BOXED WARNING

Cardiovascular Risk

  • NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk (See WARNINGS).

  • Etodolac is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS).

Gastrointestinal Risk

  • NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events (See WARNINGS).

 

ETODOLAC SUMMARY

Etodolac is a pyranocarboxylic acid chemically designated as (±) 1, 8-diethyl-1,3,4,9-tetrahydropyrano-[3,4-b]indole-1-acetic acid.

Etodolac is indicated for acute and long-term use in the management of signs and symptoms of osteoarthritis. Etodolac is also indicated for the management of pain.


See all Etodolac indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Etodolac

A multicentric, randomized, comparative clinical trial to evaluate the efficacy and safety of S-etodolac in the treatment of osteoarthritis in Indian patients. [2010.07]
OBJECTIVE: To compare the efficacy and safety of S-etodolac with etodolac in the treatment of osteoarthritis in Indian patients... CONCLUSION: The present study has established the efficacy, tolerability and safety of S-etodolac extended release tablets in the treatment of osteoarthritis in Indian patients.

Efficacy and safety of etodolac-paracetamol fixed dose combination in patients with knee osteoarthritis flare-up: a randomized, double-blind comparative evaluation. [2010]
OBJECTIVE: To evaluate the efficacy and safety of etodolac-paracetamol combination in comparison with etodolac alone in patients with knee osteoarthritis (OA) flare-up. METHODS: In this double-blind, double-dummy, randomized, comparative, multicentric, parallel group study, 220 patients of either sex in the age range of 40 to 70 years with an OA flare-up were randomized either to etodolac (300 mg)-paracetamol (500 mg) combination or etodolac (300 mg) alone twice a day for 10 days...

A multicentric, randomized, comparative clinical trial to evaluate the efficacy and safety of S-etodolac in the treatment of osteoarthritis in Indian patients. [2010]
treatment of osteoarthritis in Indian patients... CONCLUSION: The present study has established the efficacy, tolerability and

Evaluation of adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs. [2007.03]
OBJECTIVE: To evaluate adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs... Monitoring for adverse effects should be considered when nonsteroidal anti-inflammatory drugs are used to treat dogs with chronic pain.

Etodolac versus dexamethasone effect in reduction of postoperative symptoms following surgical endodontic treatment: a double-blind study. [2006.06]
OBJECTIVE: The purpose of this prospective study was to analyze the effect of etodolac versus dexamethasone in reducing postoperative pain in patients who had surgical endodontic treatment using a strict protocol... CONCLUSION: Postoperative pain following endodontic surgical treatment is not uncommon. Etodolac as well as dexamethasone might serve as a pain relief measure for postoperative pain in these patients.

more studies >>

Clinical Trials Related to Etodolac

MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Ankle Sprains [Recruiting]

Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM) [Terminated]
An Open Label, Multi-Center, Phase II Study to Investigate the Safety and Efficacy of SDX-101 (R-Etodolac) in Patients with Relapsed or Refractory Multiple Myeloma (MM)

A Study to Verify the Efficacy of YM177 (Celecoxib) in Postoperative Pain Patients [Recruiting]
Aim of the study is to compare efficacy and safety of YM177 with placebo and etodolac in patients with postoperative pain.

MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Tendonitis and Bursitis of the Shoulder [Recruiting]

Safety and Efficacy of SDX-101 (R-Etodolac) in Combination With Chlorambucil, and That of Chlorambucil Alone, in Patients With Chronic Lymphocytic Leukemia (CLL) [Terminated]
This is a Phase 2, multi-center, open label, randomized clinical study to evaluate the safety and efficiency of SDX-101 in combination with chlorambucil (CLB) and chlorambucil alone in Chronic Lymphocytic Leukaemia (CLL) patients. The study treatment period will be approximately 24-26 weeks with a follow-up period of approximately 8 weeks. Following the end of treatment, patients with a confirmed complete response, partial response or stable disease will be followed for up to 2 years to assess time to disease progression. Approximately 80 patients with documented diagnosis of B-cell CLL by standard clinical and immunophenotyping criteria will be enrolled into the SDX-101-03 study. This study is being conducted in the following European countries: France, Germany, Poland, Sweden and the United Kingdom.

more trials >>

Reports of Suspected Etodolac Side Effects

Pyrexia (8)Pneumonia (8)Asthenia (6)Fatigue (5)Completed Suicide (5)Neoplasm Malignant (5)Asthma (4)Drug Ineffective (4)Urticaria (4)Neoplasm Progression (4)more >>


PATIENT REVIEWS / RATINGS / COMMENTS

Based on a total of 1 ratings/reviews, Etodolac has an overall score of 9. The effectiveness score is 8 and the side effect score is 8. The scores are on ten point scale: 10 - best, 1 - worst.
 

Etodolac review by 51 year old female patient

  Rating
Overall rating:  
Effectiveness:   Considerably Effective
Side effects:   Mild Side Effects
  
Treatment Info
Condition / reason:   Osteo-arthritis
Dosage & duration:   400mg taken twice a day for the period of 3 yrs.
Other conditions:   Asthma, Hashimoto's Thyroiditis, Vitiligo, Hypertension, Anxiety
Other drugs taken:   Lisinopril, Lexapro, Levothroid, Asmanex, Albuterol
  
Reported Results
Benefits:   It is moderately effective in reducing the pain, and very effective in reducing the inflammation, swelling and heat in the joints. I had not realized just how effective it is, until I ran out recently, and was without it for a few days. I guess I had forgotten how debilitating OA can be. Without it, I walk with a cane- with it, I don't need a cane, and can even walk for a mile or so for exercize, without 'paying for it' the next day.
Side effects:   At first it made me pretty drowsy. After about three weeks, my body adjusted to it, and the drowsiness went away. I have to be sure to take Etodolac after eating a meal, or it causes rather pronounced nausea. I've found that it has to be an actual meal, too. Just a nibble of something isn't enough to prevent the upset stomach.
Comments:   I am severely allergic to Aspirin and Naproxyn, so cannot take these for the pain and inflammation of osteoarthritis. I developed OA in both knees after injuring the cartilage and the arthroscopic surgery to try to repair the damage. My left knee still has a little cartilage, but the right knee has bone on bone. I had been taking Vioxx, which worked very well, but then it was pulled off the market. Mobic did not work very well, so we went on to Etodolac. Once a year, I have to go in and get bloodwork done, to make sure I have not developed any liver damage.

See all Etodolac reviews / ratings >>

Page last updated: 2013-02-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012